---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-022159"
form_type: "8-K"
ticker: "NSPR"
cik: "0001433607"
company_name: "InspireMD, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:35:21.308650+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# InspireMD Q2 net loss widens to $13.2M ($0.26/share); revenue up 2.3% to $1.78M

## Summary
- Net loss of $13.2M ($0.26 per share) vs $7.9M loss ($0.22) in Q2 2024; operating expenses surged 55% to $13.3M.
- Revenue of $1.78M, up 2.3% YoY; gross profit fell 5.4% to $313k; cash & securities dropped to $19.4M from $34.6M.
- Company raised $58M in gross proceeds from equity private placement and warrant exercise.
- FDA granted PMA approval for CGuard Prime carotid stent; US commercial launch commenced; CE Mark under MDR also received.
- Appointed Mike Lawless as CFO and added Raymond W. Cohen to Board of Directors.

## SEC filing metadata
- accession: 0001641172-25-022159
- form_type: 8-K
- ticker: NSPR
- cik: 0001433607
- company_name: InspireMD, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1433607/000164117225022159/0001641172-25-022159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1433607/000164117225022159/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-022159
- JSON: https://secwatch.observer/filing/0001641172-25-022159.json
- Plain text: https://secwatch.observer/filing/0001641172-25-022159.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.